MBX Biosciences, Inc. (MBX)

MBX Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	132.87	30.52	24.21
Short-Term Investments	144.2	50.15	18.25
Cash & Short-Term Investments	277.06	80.68	42.46
Cash Growth	552.51%	90.00%	-
Other Receivables	0.86	0.21	0.14
Receivables	0.86	0.21	0.14
Prepaid Expenses	2.41	2.45	1.52
Other Current Assets	0.84	0.13	0.08
Total Current Assets	281.17	83.47	44.21
Property, Plant & Equipment	1.18	0.67	0.84
Other Long-Term Assets	0.05	0.05	0.04
Total Assets	282.4	84.18	45.1
Accounts Payable	5	1.39	0.98
Accrued Expenses	5.75	2.38	2.32
Current Portion of Leases	0.17	0.15	0.14
Total Current Liabilities	10.92	3.93	3.43
Long-Term Leases	0.04	0.17	0.32
Other Long-Term Liabilities	0.07	0.19	0.07
Total Liabilities	11.03	4.29	3.82
Common Stock	0.01	0	0
Additional Paid-In Capital	393.18	3.05	0.41
Retained Earnings	-121.92	-75.58	-43.02
Comprehensive Income & Other	0.11	0.06	0
Total Common Equity	271.37	-72.47	-42.61
Shareholders' Equity	271.37	79.89	41.27
Total Liabilities & Equity	282.4	84.18	45.1
Total Debt	0.21	0.32	0.46
Net Cash (Debt)	276.85	80.35	42
Net Cash Growth	559.17%	91.31%	-
Net Cash Per Share	20.11	6.56	5.24
Filing Date Shares Outstanding	33.42	15.11	8.02
Total Common Shares Outstanding	33.38	15.11	8.02
Working Capital	270.25	79.54	40.78
Book Value Per Share	8.13	-4.80	-5.31
Tangible Book Value	271.37	-72.47	-42.61
Tangible Book Value Per Share	8.13	-4.80	-5.31
Machinery	1	0.24	0.23
Construction In Progress	0	0	-
Leasehold Improvements	0.39	0.37	0.35

Source: S&P Capital IQ. Standard template. Financial Sources.